Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. KMS Medisurgi's cash to debt ratio for the quarter that ended in Mar. 2026 was 1.43.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, KMS Medisurgicould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for KMS Medisurgi's Cash-to-Debt or its related term are showing as below:
BOM:540468'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04 Med: 0.11 Max: 1.43
Current: 1.43
During the past 13 years, KMS Medisurgi's highest Cash to Debt Ratio was 1.43. The lowest was 0.04. And the median was 0.11.
BOM:540468's Cash-to-Debt is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.635
vs BOM:540468: 1.43
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
KMS Medisurgi Cash-to-Debt Related Terms
KMS Medisurgi Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for KMS Medisurgi's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:540468 vs ISRG, BDX, MDLN: Cash-to-Debt Comparison
For the Medical Instruments & Supplies subindustry, KMS Medisurgi's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KMS Medisurgi Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KMS Medisurgi's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where KMS Medisurgi's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KMS Medisurgi (BOM:540468) has a Cash-to-Debt of 1.43 as of Mar. 2026. This is 1200% above median its historical median of 0.11. Over the past decade, KMS Medisurgi's Cash-to-Debt has ranged from 0.04 to 1.43.
Is KMS Medisurgi's Cash-to-Debt too high?
KMS Medisurgi's current Cash-to-Debt of 1.43 is 1200% above median its 10-year median of 0.11. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 1.43. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. KMS Medisurgi's value of 1.43 is 12.5% below this industry median. Overall, KMS Medisurgi has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does KMS Medisurgi's Cash-to-Debt compare to ISRG and BDX?
KMS Medisurgi's Cash-to-Debt of 1.43 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash-to-Debt is 1.64. KMS Medisurgi's value of 1.43 is 12.5% below this benchmark. Historically, KMS Medisurgi's own Cash-to-Debt has ranged from 0.04 to 1.43 over the past decade. While the company's 10-year median is 0.11 vs. the industry median of 1.64, KMS Medisurgi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KMS Medisurgi's current Cash-to-Debt of 1.43 is 12.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KMS Medisurgi's current Cash-to-Debt is 1.43, which is 1200% above median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KMS Medisurgi stock overvalued right now?
KMS Medisurgi (BOM:540468) has a current Cash-to-Debt of 1.43. The stock's GF Value™ is ₹111.52, compared to a current price of ₹132.80 — trading 19.1% above its estimated fair value. The current Cash-to-Debt is 1.43, which is 1200% above median its 10-year median of 0.11 and 12.5% below the Medical Devices & Instruments industry median of 1.64. KMS Medisurgi's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For KMS Medisurgi (BOM:540468), the current Cash-to-Debt is 1.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KMS Medisurgi (BOM:540468) Overvalued in 2026?
Based on GuruFocus' analysis, KMS Medisurgi stock appears to be overvalued.
The current stock price of ₹132.80 is trading 19.1% above its estimated GF Value™ of ₹111.52.
Key valuation signals for BOM:540468:
Cash-to-Debt: 1.43 (1200% above median its 10-year median of 0.11)
GF Value™: ₹111.52 vs. price of ₹132.80 (19.1% above fair value)
Industry Position: 12.5% below the Medical Devices & Instruments median
No single metric tells the full story. See the BOM:540468 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KMS Medisurgi Ltd manufactures surgical tapes and dressings for hospitals, institutions, trade associations, exporters, and importers. The company manufactures and undertakes job work of various substartes like non-woven fabrics, PU films, cotton fabrics, and taffeta silk fabrics with adhesive. The company's international presence includes Vietnam, Dubai, Europe, Australia, Cambodia, India, Africa, Philippines, Russia, Pakistan, Bangladesh, and the USA. The company derives revenue from the sale of goods.
79GF Score
Get the complete analysis for BOM:540468
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540468 has been successfully added to your 
